Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408634 | 0.87 | CSF1R (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20448945 | 0.87 | CSF1R (0.42) | LPLLIPGAAK1CA1CA2 | |
| SCHEMBL29623476 | 0.85 | CSF1R (0.43) | LPLLIPGAAK1CA1CA2 | |
| SCHEMBL130370 | 0.85 | CSF1R (0.43) | LPLLIPGAAK1CA1CA2 | |
| SCHEMBL15788155 | 0.85 | CSF1R (0.43) | LPLLIPGAAK1CA1CA2 | |
| SCHEMBL16290518 | 0.82 | LPL (0.45) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1328329 | 0.82 | LPL (0.45) | LPLLIPGAAK1CA1CA2 | |
| SCHEMBL253525 | 0.82 | LPL (0.45) | LPLLIPGAAK1CA1CA2 | |
| SCHEMBL29556201 | 0.82 | LPL (0.45) | LPLLIPGAAK1CA1CA2 | |
| SCHEMBL2412157 | 0.82 | LPL (0.41) | LPLLIPGAAK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113563244-A | Substituted aza five-membered ring compound and application thereof in medicine | 广东东阳光药业有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | LPL 2319/4885LIPG 2868/4885AAK1 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.